107 related articles for article (PubMed ID: 3005569)
1. Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.
Thorsett ED; Harris EE; Aster SD; Peterson ER; Snyder JP; Springer JP; Hirshfield J; Tristram EW; Patchett AA; Ulm EH
J Med Chem; 1986 Feb; 29(2):251-60. PubMed ID: 3005569
[TBL] [Abstract][Full Text] [Related]
2. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme.
Patchett AA; Cordes EH
Adv Enzymol Relat Areas Mol Biol; 1985; 57():1-84. PubMed ID: 2994404
[TBL] [Abstract][Full Text] [Related]
3. Chemical design of cilazapril.
Attwood MR
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):133S-137S. PubMed ID: 2548550
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
Oizumi K; Koike H; Sada T; Miyamoto M; Nishino H; Matsushita Y; Iijima Y; Yanagisawa H
Jpn J Pharmacol; 1988 Nov; 48(3):349-56. PubMed ID: 2851680
[TBL] [Abstract][Full Text] [Related]
5. The chemistry of enalapril.
Patchett AA
Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):201S-207S. PubMed ID: 6085275
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T
J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729
[TBL] [Abstract][Full Text] [Related]
7. Compared properties of trandolapril, enalapril, and their diacid metabolites.
Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
[TBL] [Abstract][Full Text] [Related]
8. Effect of pH on the inhibition of angiotensin converting activity by enalaprilat in the rat perfused mesenteric vascular bed.
Lindsey CJ; Bendhack LM; Paiva AC
J Pharmacol Exp Ther; 1987 Oct; 243(1):292-6. PubMed ID: 2822902
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Krapcho J; Turk C; Cushman DW; Powell JR; DeForrest JM; Spitzmiller ER; Karanewsky DS; Duggan M; Rovnyak G; Schwartz J
J Med Chem; 1988 Jun; 31(6):1148-60. PubMed ID: 2836590
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyl tripeptide analogues of enalapril.
Greenlee WJ; Allibone PL; Perlow DS; Patchett AA; Ulm EH; Vassil TC
J Med Chem; 1985 Apr; 28(4):434-42. PubMed ID: 2984419
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and enzyme inhibitory activities of new trifluoromethyl-containing inhibitors for angiotensin converting enzyme.
Ojima I; Jameison FA; Pete B; Radunz H; Schittenhelm C; Lindner HJ; Emith AE
Drug Des Discov; 1994 Feb; 11(2):91-113. PubMed ID: 8075303
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
Kubo SH; Cody RJ
Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
[TBL] [Abstract][Full Text] [Related]
13. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
Ajayi AA; Hockings N; Reid JL
Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
[TBL] [Abstract][Full Text] [Related]
14. Characterization of angiotensin converting enzyme by [3H]captopril binding.
Strittmatter SM; Snyder SH
Mol Pharmacol; 1986 Feb; 29(2):142-8. PubMed ID: 3005826
[TBL] [Abstract][Full Text] [Related]
15. Crystallographic studies of angiotensin converting enzyme inhibitors and analysis of preferred zinc coordination geometry.
Hausin RJ; Codding PW
J Med Chem; 1990 Jul; 33(7):1940-7. PubMed ID: 2362274
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors: measurement of relative inhibitory potency and serum drug levels by radioinhibitor binding displacement assay.
Jackson B; Cubela R; Johnston CI
J Cardiovasc Pharmacol; 1987 Jun; 9(6):699-704. PubMed ID: 2442537
[TBL] [Abstract][Full Text] [Related]
17. Conformational analysis and active site modelling of angiotensin-converting enzyme inhibitors.
Andrews PR; Carson JM; Caselli A; Spark MJ; Woods R
J Med Chem; 1985 Mar; 28(3):393-9. PubMed ID: 2983076
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
[TBL] [Abstract][Full Text] [Related]
19. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
Hockings N; Ajayi AA; Reid JL
Br J Clin Pharmacol; 1986 Apr; 21(4):341-8. PubMed ID: 3011046
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
